此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity (GUT BOOST)

2026年9月15日 更新者:Sara Naramore、Indiana University
Glucagon-like peptide (GLP1) drugs have quickly become a standard treatment for the adults with obesity. These drugs target the appetite control center of the brain, which clows the rate of stomach emptying, and makes a person feel full. The researchers are exploring this response in children. This study is being conducted to better understand how two food carbohydrates affect the appetite control center of the brain. The investigators want to see if a special carbohydrate powder that is mixed with 1 cup of water twice a day will appetite.

研究概览

详细说明

Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, such as semaglutide and tirzepatide, have quickly become a standard treatment for adults with obesity. Adolescents, on the other hand, have limited access to FDA-approved medications for obesity, even though semaglutide has been shown to lead to significant improvements in body mass index and co-morbidities of obesity for youth over age 12. Obesity is defined as a body mass index greater than the 95th percentile for age and sex. Moreover, GLP-1 agonists are effective in reducing appetite and food intake and result in notable weight reduction. These drugs trigger an innate physiological system of the body that, among other targets, signals the appetite control center of the brain, the hypothalamus, to convey a feeling of fullness, as well as to slow the rate of stomach emptying. This "gut-brain axis" communication system is naturally activated by digested macronutrients through their interaction with the enteroendocrine cells, particularly the L-cells which are found in greater abundance in the distal small intestine (ileum) and proximal colon. For over 15 years, the Hamaker Lab at Purdue University has researched the potential of ileal-digesting carbohydrates, such as certain types of starch, in activating L-cells to secrete GLP-1 as a dietary route towards appetite control. In long-term feeding rat and mouse trials, the investigators have shown ileal activation of the gut-brain axis and sustained increase in plasma GLP-1 that coincided with reduction in food intake and weight management using developed methods to target starch digestion to the ileum (a starch-based fabricated microsphere and precise a-amylase inhibition to slow starch digestion. Additionally, short-chain fatty acids (SCFAs) produced by dietary fiber fermentation by gut microbes trigger secretion of GLP-1 for satiation. SCFAs also reduce gut inflammation that is linked to obesity. Of note, there are other gut hormones secreted by L-cells (e.g., Gastric Inhibitory Polypeptide (GIP), Peptide YY (PYY), oxyntomodulin) that influence the gut-brain axis for appetite modulation.

Interestingly, in mouse trials with fabricated ileal-digesting carbohydrates for gut-brain axis activation, the investigators also found reduction in fatty livers of obese mice.

Even though GLP-1 agonist drugs are highly effective in reducing weight in individuals with obesity and lowering indices of associated health conditions (e.g., Hemoglobin A1c for prediabetes/diabetes), most individuals cannot remain on the medication indefinitely due to expense and side effects, and some simply prefer not to take the weight-reducing drugs, especially at a younger age. It is, therefore, timely to test a dietary approach to activate the innate GLP-1-secreting cells in the gastrointestinal tract, through a safe and inexpensive science-based carbohydrate supplement the investigators have tested and partly optimized.

For the current proposal, the investigators hypothesize that a mixture of ileal and colonic gut brain axis (GLP-1)-activating carbohydrates given as a supplement for two months to adolescents with obesity will increase plasma GLP-1 levels, increase satiation, decrease caloric intake, reduce body mass index percentile (BMI%ile), attenuate gut inflammation, and lower liver fat.

Our overall objective is to test a combination of two food carbohydrates designed to activate the gut-brain axis through GLP-1 release for physiologic appetite suppression. The investigators will examine the central hypothesis that carbohydrates that modulate the gut-brain axis represent an efficacious strategy by which to reduce appetite and body weight in adolescents with obesity.

研究类型

介入性

注册 (估计的)

62

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Brian DeBosch, MD, PhD
  • 电话号码:317-944-3774
  • 邮箱:bdebosch@iu.edu

学习地点

    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Riley Hospital for Children at IU Health

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  • Children ages 12 to ≤18 years and older with obesity, a BMI ≥95% for age and sex
  • English-speaking subjects
  • Children who have been on stable dosing of medications for 3 months which secondarily lead to weight gain, weight loss, or appetite suppression
  • Children able to stay on a stable dose of all concomitant medications throughout the study treatment period

Exclusion Criteria:

  • Females who are or planning to become pregnant or are breastfeeding
  • Children with malabsorptive disorders including inflammatory bowel disease, Celiac disease, and short bowel syndrome
  • Children with any intestinal resection
  • Children with Type 1 or Type 2 Diabetes Mellitus
  • Children taking any medications or supplements for weight loss within 30 days prior to enrollment in the study
  • Subject has any condition that, in the opinion of the investigator, would compromise the well-being of the subject or would compromise the study or prevent the subject from meeting or performing study requirements.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:gut-brain axis (GLP-1)-activating food carbohydrate supplement (raw corn starch + raw potato starch)
Intervention with GLP-1-activating carbohydrate
The primary study intervention will be providing 2-months of supplementation of either a gut-brain axis (GLP-1)-activating food carbohydrate supplement (raw corn starch + raw potato starch). Supplements will be provided as 10 gram (2 tsp) sachets containing the test or control food carbohydrates, a viscous agent (guar gum), and a fruit flavoring to be mixed with 200 ml (6.6 oz) water and consumed at breakfast and 2 hours (+/- 60 minutes) prior to dinner daily.
其他名称:
  • GLP-1-activating carbohydrate
安慰剂比较:starch-based fast-digesting placebo control (commercial maltodextrin)
Intervention with starch-based placebo
Supplements will be provided as 10 gram (2 tsp) sachets containing the placebo control food carbohydrates, a viscous agent (guar gum), and a fruit flavoring to be mixed with 200 ml (6.6 oz) water and consumed at breakfast and 2 hours (+/- 60 minutes) prior to dinner daily.
其他名称:
  • Placebo starch

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Serum GLP-1 level effect on satiation and caloric intake
大体时间:2 months
Significant and sustained elevation of postprandial plasma GLP-1 in participants taking the GLP-1-activating carbohydrate compared to the placebo control
2 months
Changes in score on the Intuitive Eating Scale for Early Adolescents
大体时间:2 months
Higher scores on the Intuitive Eating Scale for Early Adolescents in those receiving the GLP-1-activating carbohydrate. This reflects a greater satiation effect and behavior change surrounding satiety.
2 months
Changes in caloric intake
大体时间:2 months
Lower caloric intake from the 3-day food log for those consuming the GLP-1-activating carbohydrate
2 months

次要结果测量

结果测量
措施说明
大体时间
Percent change in BMI and weight
大体时间:2 months
Decrease in body mass index percentile (BMI percentile) and weight
2 months
Improvement in fecal calprotectin
大体时间:2 months
Decrease in fecal calprotectin, an indicator of intestinal inflammation, a common condition in obesity
2 months
Improvement in serum liver enzymes
大体时间:2 months
Decrease in ALT and AST indicating decreased hepatic steatosis and steatohepatitis
2 months
Changes in hepatic steatosis and fibrosis on Fibroscan
大体时间:2 months
Decrease in liver fat (CAP score) and liver stiffness as measured by transient elastography
2 months
Percent change in body fat mass
大体时间:2 months
Decrease in total body fat mass as determined by DEXA scan
2 months
Changes in gut microbiome composition
大体时间:2 months
For the gut microbiome, the investigators expect to see greater short-chain fatty acids (SCFAs), including butyrate, that is related to lower inflammation and an increase in certain beneficial SCFA-producing bacteria (e.g., families Ruminococcaceae, Lachnospiraceae, Bacteroidaceae)
2 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sara K Naramore, MD、Indiana University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年9月3日

首先提交符合 QC 标准的

2026年9月15日

首次发布 (实际的)

2026年9月16日

研究记录更新

最后更新发布 (实际的)

2026年9月16日

上次提交的符合 QC 标准的更新

2026年9月15日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

IPD information available upon request

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅